Central Nervous System Drugs Market Trends Strategies, And Opportunities In The Central Nervous System Drugs Market 2021
September 15, 2021
The Business Research Company’s Central Nervous System Drugs Global Market Report 2021: COVID-19 Impact And Recovery To 2030
LONDON, GREATER LONDON, UK, September 15, 2021 /EINPresswire.com/ -- According to the new market research report ‘Central Nervous System Drugs Global Market Report 2021: COVID-19 Impact And Recovery’ published by The Business Research Company, the central nervous system drugs market is expected to grow from $125.28 billion in 2020 to $126.89 billion in 2021 at a compound annual growth rate (CAGR) of 1.3%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $163.05 billion in 2025 at a CAGR of 6%. The strong economic growth boosted the demand for central nervous system drugs and this drove the market during the historic period.
Request For A Sample For The Global Central Nervous System Drugs Market Report:
The central nervous system (CNS) drugs market consists of sales of central nervous system drugs and related services by entities (organizations, sole traders and partnerships) that manufacture central nervous system drugs that are used in the treatment of diseases affecting the brain or spinal cord. The central nervous system integrates sensory information and instructs the body to respond accordingly. The spinal cord is a channel for signals between the brain and the rest of the body. A CNS disorder is a condition in which the brain and spinal cord’s ability to function is affected, hence affecting the body. The market for CNS disorder drugs comprises of drugs that work in different ways depending on the type of disease by suppressing or boosting the brain activities.
Trends In The Global Central Nervous System Drugs Market
Many central nervous system drug manufacturers are collaborating with other manufacturers in the industry to share technical knowledge and improve product quality. These agreements are helping anti-epileptics drugs manufacturers broaden their products and services. For instance, in January 2017, Japan's Takeda Pharmaceuticals collaborated with New York-based biotech company Ovid Therapeutics to develop TAK-935, a drug for the treatment of rare epilepsy disorders in children. Also, Israel based D-Pharm LTD. and China based Jiangsu NHWA Pharmaceutical Co. Ltd. are co-developing DP-VPA, an anti-epileptic drug. In October 2016, UCB Pharmaceuticals signed a partnership agreement with Evotec for the research and development of drugs for nervous disorders such as epilepsy, Parkinson’s and Alzheimer’s diseases.
Global Central Nervous System Drugs Market Segments:
The global central nervous system drugs market is further segmented based on type and geography.
By Type: Analgesics, Anti-Parkinson drugs, Anesthetics, Anti-Epileptics, Other CNS drugs
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others
By Route Of Administration: Oral, Parenteral, Others
By Drug Classification: Branded Drugs, Generic Drugs
By Mode Of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs
By Geography: The global CNS drugs market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa. Among these regions, the North American central nervous system drugs market accounts for the largest share in the global central nervous system drugs market.
Read More On The Report For The Global Central Nervous System Drugs Market At:
Central Nervous System Drugs Global Market Report 2021 is one of a series of new reports from The Business Research Company that provides central nervous system drugs market overviews, analyzes and forecasts market size and growth for the global central nervous system drugs market, central nervous system drugs market share, central nervous system drugs market players, central nervous system drugs market segments and geographies, central nervous system drugs market’s leading competitors’ revenues, profiles and market shares. The central nervous system drugs market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.
Read Central Nervous System Drugs Global Market Report 2021 from The Business Research Company for information on the following:
Data Segmentations: Market Size, Global, By Region And By Country; Historic And Forecast Size, And Growth Rates For The World, 7 Regions And 12 Countries
Central Nervous System Drugs Market Organizations Covered: Biogen Inc, F. Hoffmann-La Roche Ltd, Johnson & Johnson, Pfizer Inc, Novartis AG.
Regions: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Interested to know more about The Business Research Company?
The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets.
Get a quick glimpse of our services here:
Here is a list of reports from The Business Research Company similar to the Central Nervous System Drugs Global Market Report 2021:
Pharmaceutical Drugs Global Market Report 2021 : COVID-19 Impact And Recovery To 2030
Anesthetics Global Market Report 2021 : COVID-19 Implications And Growth To 2030
Generic Pharmaceuticals Global Market Report 2021 : COVID-19 Growth And Change To 2030
Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293